- cafead May 22, 2024 at 11:32: AM
via Eli Lilly has reported promising results from the Phase III VIVID-1 study of mirikizumab in treating moderately to severely active Crohn’s disease.
The randomised, treat-through, double-blind trial assessed the safety and efficacy of mirikizumab versus placebo and ustekinumab, an active control.
article source
The randomised, treat-through, double-blind trial assessed the safety and efficacy of mirikizumab versus placebo and ustekinumab, an active control.
article source